We have many catalysts coming at us in a short tim
Post# of 148175
1 Pending eua -> then possible full approal
- Either way possible OWS funding and gov deal of $2-$5b
2 NASDAQ (think of the institutions and robin hooders sitting on the sidelines)
3 BLA submission -> starts the clock to more revenue and/or full approval which will make it easier for expanded label approval in the future.
I think $50 within Q1 is def possible, just based on demand to get into the company. Many have talked about the P/E ratio of start up biotechs, and we have a winner for a therapeutic for HIV and Covid